An observational study found combined associations of heavy methamphetamine use and APOE ε4 status with selected frontal brain measures. It did not establish that an individual carrier would develop dementia or that methamphetamine caused the anatomical differences.
The researchers compared 77 people with chronic heavy methamphetamine use and 226 nonusers, separating each group by APOE ε4 carrier status. MRI assessed cortical volume, thickness and selected subcortical structures, while cognitive testing assessed performance. Twenty-six methamphetamine participants carried ε4, making the combined-exposure subgroup relatively small.
Methamphetamine history was associated with selected thinner or smaller cortical regions, lower motor scores and larger volumes in several subcortical structures. Participants with both methamphetamine history and ε4 had particularly small volumes in selected frontal regions. These findings were region-specific: they were not a uniform reduction throughout the brain. Larger subcortical volumes also cannot be assumed to represent either better function or a particular cellular mechanism.
Neither genotype nor drug history was randomly assigned, and the cross-sectional design did not observe the rate of anatomical change within individuals over time. Age-related comparisons therefore should not be described as measured longitudinal progression. Small carrier groups also prevented strong separation of allele-dose effects. A proposed explanation involving inflammation remains an interpretation rather than direct proof from volume alone. The study supplies no dementia diagnosis, individualized prognosis or impairment cutoff. Its contribution is a hypothesis about joint genetic and exposure-related vulnerability that requires longitudinal replication, rather than a deterministic account of any person’s cognitive future.
See the difference between cortical thickness and gray-matter volume.